You don't hire a public-company CFO away from a household-name retailer to manage a melting ice cube. Cencora (NYSE:COR) — the distributor formerly known as AmerisourceBergen — just did exactly that, and stacked it on top of a raised guide and two bolt-on deals in a single quarter. Almost nobody noticed.
Why it moved
Start with the print: fiscal Q2 revenue of $78.4B, up 3.8% YoY, with management raising full-year adjusted EPS guidance to $17.65-$17.90. Distributors don't raise into uncertainty unless volumes and pricing are holding. Then leadership: Eva C. Boratto joins as EVP & CFO on June 29, 2026 from the Bath & Body Works finance seat, succeeding retiring James F. Cleary — a clean, well-telegraphed handoff, not a fire drill.
| Metric | Figure |
|---|---|
| Q2 FY26 revenue | $78.4B |
| Revenue growth YoY | +3.8% |
| FY26 adj. EPS guidance | $17.65-$17.90 |
| EyeSouth retina deal | $1.1B |
What it means for you
The brand-name CFO is the tell. You recruit a finance chief of that caliber to run capital allocation at scale — and the playbook is already visible: the $1.1B EyeSouth retina deal deepens specialty, and the Covetrus-MWI tie-up built a combined animal-health platform. Bolt-ons in growth verticals, funded by a steady core. The thing to watch is whether Boratto leans into buybacks, more specialty M&A, or both.
Bottom line: I'm treating COR as a buy-and-hold steady compounder — I'd accumulate on dips and let the raised guide and new CFO do the work, rather than wait for a catalyst that this kind of name rarely delivers in one pop.